Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease

Eur J Gastroenterol Hepatol. 2012 Jun;24(6):695-701. doi: 10.1097/MEG.0b013e328351c1c2.

Abstract

Objective: The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn's disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO.

Methods: Immunohistochemistry was used. A total of 10 high power fields were counted for each patient.

Results: IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn's disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy.

Conclusion: IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • CD11c Antigen / metabolism
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / enzymology
  • Colitis, Ulcerative / immunology
  • Crohn Disease / drug therapy
  • Crohn Disease / enzymology
  • Crohn Disease / immunology
  • Epithelial Cells / enzymology
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoenzyme Techniques
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism*
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / enzymology*
  • Inflammatory Bowel Diseases / immunology
  • Infliximab
  • Intestinal Mucosa / enzymology
  • Male
  • Middle Aged
  • Salicylates / therapeutic use
  • Toll-Like Receptor 4 / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD11c Antigen
  • CD68 antigen, human
  • Gastrointestinal Agents
  • Glucocorticoids
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Salicylates
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • Infliximab